GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » COSMOS Pharmaceutical Corp (TSE:3349) » Definitions » Debt-to-EBITDA

COSMOS Pharmaceutical (TSE:3349) Debt-to-EBITDA : 0.31 (As of May. 2024)


View and export this data going back to 2004. Start your Free Trial

What is COSMOS Pharmaceutical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

COSMOS Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2024 was 円6,512 Mil. COSMOS Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2024 was 円27,551 Mil. COSMOS Pharmaceutical's annualized EBITDA for the quarter that ended in May. 2024 was 円110,988 Mil. COSMOS Pharmaceutical's annualized Debt-to-EBITDA for the quarter that ended in May. 2024 was 0.31.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for COSMOS Pharmaceutical's Debt-to-EBITDA or its related term are showing as below:

TSE:3349' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.2   Med: 0.41   Max: 0.88
Current: 0.61

During the past 13 years, the highest Debt-to-EBITDA Ratio of COSMOS Pharmaceutical was 0.88. The lowest was 0.20. And the median was 0.41.

TSE:3349's Debt-to-EBITDA is ranked better than
77.98% of 445 companies
in the Healthcare Providers & Services industry
Industry Median: 2.45 vs TSE:3349: 0.61

COSMOS Pharmaceutical Debt-to-EBITDA Historical Data

The historical data trend for COSMOS Pharmaceutical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

COSMOS Pharmaceutical Debt-to-EBITDA Chart

COSMOS Pharmaceutical Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.28 0.20 0.20 0.36 0.63

COSMOS Pharmaceutical Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.38 0.31 0.31 -

Competitive Comparison of COSMOS Pharmaceutical's Debt-to-EBITDA

For the Pharmaceutical Retailers subindustry, COSMOS Pharmaceutical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


COSMOS Pharmaceutical's Debt-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, COSMOS Pharmaceutical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where COSMOS Pharmaceutical's Debt-to-EBITDA falls into.



COSMOS Pharmaceutical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

COSMOS Pharmaceutical's Debt-to-EBITDA for the fiscal year that ended in May. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6512 + 27551) / 53742
=0.63

COSMOS Pharmaceutical's annualized Debt-to-EBITDA for the quarter that ended in May. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6512 + 27551) / 110988
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (May. 2024) EBITDA data.


COSMOS Pharmaceutical  (TSE:3349) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


COSMOS Pharmaceutical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of COSMOS Pharmaceutical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


COSMOS Pharmaceutical Business Description

Traded in Other Exchanges
Address
4 floor,10th first Fukuoka S Building Museum, Hakataekihigashi 2-chome, Fukuoka, JPN, 812-0013
COSMOS Pharmaceutical Corp manages retail drugstores in Japan. The company places a emphasis on convenience regarding its product selection, which includes medical products, health and beauty aids, personal-care items, discount cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, alcoholic beverages, tobacco, insect repellent, and miscellaneous everyday consumables. The majority of the company's revenue is derived from common grocery sales. Cosmos also operates a private grocery brand called ON 365.

COSMOS Pharmaceutical Headlines

No Headlines